| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
BETHESDA, Md.—RegeneRx Biophar-maceuticals reported in early August that it had begun a collaboration with the Division of Cardiology at Children's National Medical Center (CNMC) in Washington, D.C., to study thymosin beta 4 (TB4). The goal is to explore TB4's ability to treat degenerative muscle diseases that often result in cardiomyopathy—a progressive deterioration and weakening of the heart.
 
More than 84,000 patients with degenerative muscular dystrophy diseases exist in the United States currently, with about 50,000 of them having cardiomyopathy. Cardiomyopathy can lead to arrhythmia, heart failure and sudden death, and for most patients, transplantation of a new heart is the only viable treatment. RegeneRx hopes to change that situation with TB4.
 
Dr. Christopher Spurney, assistant professor of pediatrics at CNMC, is leading the project, which will study the effects of TB4 in non-human models that have a disease similar to human Duchenne muscular dystrophy and go on to develop cardiomyopathy.
 
"This collaboration resulted originally from an article published in Nature last November showing that our proprietary product was effective in preventing functional and pathological damage to the myocardium in mouse studies," notes J.J. Finkelstein, president and chief executive officer of RegeneRx. "That gained a lot of attention, and for some time already we had discussed with CNMC how we might collaborate since (we are) both in the metro D.C. area. This seemed like the logical project for us to pursue together."
 
The study published in Nature involved a series of 60 mice at the University of Texas Southwestern Medical Center, in which myocardial infarction was induced. A third of the mice were given a placebo, another third received intracardiac administration of TB4 and the remainder received TB4 through a tail vein. In the two active groups that received TB4, there was statistically significant reduction of scarring of the heart and statistically significant increase in heart function, Finkelstein says.
 
"This is a very exciting study as it may relate to previously published work showing TB4's ability to protect and repair the heart after an acute myocardial infarction," Spurney says. "We look forward to testing it in our models to see if we can produce similar results. If TB4 is shown to be protective, we would hope to move into human clinical trials."
 
Dr. Allan Goldstein, chairman of biochemistry and molecular biology at the George Washington University Medical School in Washington, D.C.—and also chief scientific advisor to RegeneRx—is encouraged by the partnering of RegeneRx and CNMC, citing Spurney's team as being "among the most experienced in the world in degenerative muscle diseases and their effects on the heart."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue